【海正是哪个国家的品牌？】

始创于1956年的浙江海正药业股份有限公司（股票代码600267，以下简称“海正药业”）秉承“执著药物创新，成就健康梦想”的使命和“成为广受尊重的全球化制药企业”的愿景，致力于整合药物研发与生产资源，为全球客户提供更好的产品和服务，通过美国FDA、欧盟EDQM、澳大利亚TGA、韩国KFDA等官方认证的品种达到40多个，销往全球30多个国家和地区。

2009年，公司荣获“全国五一劳动奖状”，海正、HISUN及图形被认定为“中国驰名商标”，入选“中国万种微生物基因组计划”和“国家重大（磅）级药物品种产业化技术创新联盟”。因圆满完成“抗甲流药物中间体生产”的国家任务，受到省政府的通令嘉奖。

2010年，公司入选浙江省医药工业“十强企业”，并荣获“国内最佳产品线十佳工业企业”称号，同时被誉为“金蜜蜂奖成长型企业”。

海正作为国家首批创新型企业，早在2001年建立了国家认定的企业技术中心和博士后科研工作站，目前拥有专职研发人员400多名。技术中心设有50多个单元实验室，研发领域涵盖化学合成、微生物发酵、生物技术、天然植物提取及制剂开发等多个方面，产品治疗领域涉及抗肿瘤、心血管系统、抗感染、抗寄生虫、内分泌调节、免疫抑制、抗抑郁等。

海正与国内30多家知名的科研院校保持着密切的协作关系，在多所大学建有实验室。与美国、日本、欧洲等国外研究机构开展新药合作研究开发，与国外大公司通过项目转移、委托开发等模式进行合作。海正的年均R&D投入占销售额的8%以上。

海正的另一个关键性战略是保持并拓展其国际客户网络。通过提供全面的产品和服务，海正80%以上的原料药产品销往30多个国家，特别是在欧美地区拥有领先的市场份额。

从1989年起，海正开始欧美市场的药政注册工作。1992年，海正获得了首批FDA认证。美国FDA官员先后十次前来海正进行检查，欧盟、德国、英国、日本、韩国、澳大利亚等官方也相继来检查。目前，海正共有18个产品已获得批准进入美国市场，14个产品获得CEP证书。

海正重视EHS一体化体系建设工作，融合了ISO14001环境管理体系、OHSAS18001职业健康安全管理体系及SA8000社会责任管理体系。海正累计在环保领域投入2.3亿元，约占公司生产性固定资产总额的12%。每年EHS运行费用约在生产成本的5-6%。这是公司为全球客户生产环保型产品的不懈努力的一部分。

发展历程:

2010年：海正药业（美国）有限公司在美国新泽西普林斯顿成立

2009年：海正药业与雅赛利香港有限公司共同设立的合资子公司雅赛利（台州）制药有限公司成立。

2000年：海正药业发行4000万股A股在上海证券交易所上市。

1998年：集团公司联合境内外七家机构发起设立浙江海正药业股份有限公司。

英文翻译：Founded in 1956, Zhejiang Haizheng Pharmaceutical Co., Ltd. (Stock Code: 600267, hereinafter referred to as "Haizheng pharmaceutical") adheres to the mission of "persisting in drug innovation, achieving health dream" and the vision of "becoming a well respected global pharmaceutical enterprise", is committed to integrating drug R & D and production resources, providing better products and services for global customers through the US FDA, Europe There are more than 40 officially certified varieties such as alliance EDQM, Australia TGA and Korea KFDA, which are sold to more than 30 countries and regions around the world. In 2009, the company won the "National May 1st Labor Award", Haizheng, Hisun and graphics were recognized as "China's famous trademark", and were selected into "China's ten thousand microbial genome project" and "national major (pound) pharmaceutical product industrialization technology innovation alliance". He was awarded by the provincial government for successfully completing the national task of "production of intermediate of anti-A drugs". In 2010, the company was selected as one of the "top ten pharmaceutical enterprises" in Zhejiang Province, and won the title of "top ten industrial enterprises with the best product line in China", and also known as the "Golden Bee award growth enterprise". Haizheng, as one of the first batch of innovative enterprises in China, established the national enterprise technology center and postdoctoral research workstation as early as 2001. At present, Haizheng has more than 400 full-time R & D personnel. The technology center has more than 50 unit laboratories, and the research and development fields cover chemical synthesis, microbial fermentation, biotechnology, natural plant extraction and preparation development. The product treatment fields involve anti-tumor, cardiovascular system, anti infection, anti parasite, endocrine regulation, immunosuppression, anti depression, etc. Haizheng keeps close cooperation with more than 30 well-known scientific research institutions in China and has laboratories in many universities. Cooperation in research and development of new drugs is carried out with foreign research institutions such as the United States, Japan and Europe, and cooperation with foreign large companies is carried out through project transfer, commissioned development and other modes. Haizheng's annual R & D investment accounts for more than 8% of sales. Another key strategy of Haizheng is to maintain and expand its international customer network. By providing comprehensive products and services, more than 80% of Haizheng's API products are sold to more than 30 countries, especially in Europe and the United States, with leading market share. Since 1989, Haizheng has started the drug administration registration in the European and American markets. In 1992, Haizheng obtained the first batch of FDA certification. FDA officials from the United States have come to Haizheng for inspection ten times, and officials from the European Union, Germany, the United Kingdom, Japan, South Korea and Australia have also come to inspect. At present, a total of 18 products of Haizheng have been approved to enter the U.S. market, and 14 products have obtained CEP certificates. Haizheng attaches great importance to the construction of EHS integrated system, integrating ISO14001 environmental management system, OHSAS18001 occupational health and safety management system and SA8000 social responsibility management system. Haizheng has invested 230 million yuan in the field of environmental protection, accounting for about 12% of the company's total productive fixed assets. The annual EHS operation cost is about 5-6% of the production cost. This is part of the company's unremitting efforts to produce environmentally friendly products for global customers. Development history: 2010: Haizheng Pharmaceutical (USA) Co., Ltd. was established in Princeton, New Jersey, USA 2009: yasaili (Taizhou) Pharmaceutical Co., Ltd., a joint venture subsidiary of Haizheng pharmaceutical and yasaili Hong Kong Co., Ltd. was established. In 2000, Haizheng pharmaceutical issued 40 million a shares to be listed on the Shanghai Stock Exchange. 1998: the group company initiated the establishment of Zhejiang Haizheng Pharmaceutical Co., Ltd. in cooperation with seven organizations at home and abroad.

本文链接： https://www.waitui.com/brand/5bb4e0a88.html 联系电话：0576-88827890